Head and neck experts show major elective target variation despite identical gross tumor volumes
Across 32 experts, agreement fell to Dice 0.45 for elective nasopharyngeal targets despite identical starting GTV and OAR contours.
Across 32 experts, agreement fell to Dice 0.45 for elective nasopharyngeal targets despite identical starting GTV and OAR contours.
In a randomized trial, early oral nutritional supplementation reduced >5% weight loss from 80.7% to 65.4% during nasopharyngeal chemoradiotherapy.
Among 54 patients receiving definitive locoregional RT, metastasis-directed therapy was associated with 82% versus 28% two-year recurrence-free survival.
In 60 patients with postradiation skull-base osteoradionecrosis, ultrasound-guided flap reconstruction showed approximately 93–95% survival, with prolonged surgery associated with necrosis.
In 256 nasopharyngeal cancer patients, brain necrosis occurred in 6.3% after proton therapy versus 5.1% after photon IMRT, without a significant difference.
Among 8,798 patients with nasopharyngeal carcinoma, regular surveillance was associated with better overall survival, particularly when distant-site imaging was performed.
One-third of patients developed malnutrition during nasopharyngeal RT, while prophylactic enteral nutrition was associated with better post-treatment weight stabilization.
In 752 NPC patients, 45-Gy EQD2 elective nodal irradiation achieved 97.3% 5-year regional control with only 0.7% elective-volume failures.
In 331 Danish NPC patients, five-year failure rates were similar by EBV status, while distant relapse was concentrated in locally advanced disease.
Among long-term NPC survivors treated with IMRT, radiation-related second malignancy incidence reached 6.66% at 15 years.
Adding advanced extranodal extension to N3 modestly improved prognostic discrimination and identified patients with substantially greater distant failure risk.
SPC-guided planning reduced larynx and parotid doses without compromising target coverage in a 200-patient retrospective nasopharyngeal carcinoma series.
Reducing the PTV–temporal lobe overlap dose to 66 Gy lowered five-year radiographic temporal lobe injury from 36.2% to 23.2%.
Adding parotid–target overlap shape features improved moderate-to-severe xerostomia prediction from AUC 0.66 to 0.78.
External validation achieved AUC 0.986, while modeled risk-adapted surveillance reduced visits by 90.0–98.5% and identified every observed failure.